PRKAA2 and type 2 diabetes mellitus: Thus, during the last decade there has been a major drive to develop small-molecule AMPK activators, and the identification of A769662 held promise in drug development for the treatment of T2D (156) until it was reported that A769662 predominantly activates AMPKβ1-containing complexes (70), which do not seem to exist in human skeletal muscle (69, 76).